BIORA THERAPEUTICS, INC.
BIORA THERAPEUTICS, INC. (BIOR): 4 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.4 months
D/E -1.14 · 0% dilution
Lead: Phase 1
4 candidates
N/A
N/A
A transparent, data-derived signal for BIORA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$3.2M
Quarterly Burn
$8.7M
Runway
1.4 mo
Revenue
$32K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in BIORA THERAPEUTICS, INC.'s pipeline?
BIORA THERAPEUTICS, INC. (BIOR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIORA THERAPEUTICS, INC.'s lead drug candidate?
BIORA THERAPEUTICS, INC.'s most advanced tracked candidate is bt-001 (Preclinical) for ulcerative colitis.
What is BIORA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIORA THERAPEUTICS, INC. has approximately 1.4 months of cash runway.
Who is the CEO of BIORA THERAPEUTICS, INC.?
Adi Mohanty is the chief executive officer of BIORA THERAPEUTICS, INC. (BIOR).
Get the full picture on BIORA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.